A small retrospective study of women receiving taxane therapy for breast or ovarian cancer while pregnancy showed no statistically significant outcomes in maternal or fetal health.
Read the abstract here
Related Topics
OCRA’s Rivkin Ovarian Cancer Research Symposium Convenes A Scientific Community Ready to Accelerate Progress
Researchers, clinicians, and advocates gather to share findings and build collaborations More than 375 researchers, clinicians, and advocates from across the ovarian cancer community gathered in Philadelphia for the 16th Biennial Rivkin Ovarian Cancer Research Symposium, presented for the first time by Ovarian Cancer Research Alliance (OCRA), from October 16-18. Founded in 1996 by the … Continued
The Overview: June 2026
Nearly 500 people have already registered for OCRA’s International Gynecologic Cancer Conference®—the largest conference dedicated to the gynecologic cancer community—taking place on September 16–17. The conference is free, online, and open to all, and will include programming for ovarian, endometrial, cervical, and rare gynecologic cancers. For the first time, each of these diseases will have a dedicated Ask the Experts session. Learn … Continued
Inside the Think Tank: Stopping Ovarian Cancer Before it Starts
On June 1–2, the Ovarian Cancer Observatory—part of OCRA’s broader investment in research initiatives—convened its first in-person Forum in Vancouver. Roughly 50 of the field’s brightest clinicians, pathologists, and epidemiologists gathered for what became, in essence, a two-day think tank on preventing ovarian cancer. The Observatory is funded through a grant from OCRA and was … Continued